Elotuzumab - AbbVie/Bristol-Myers Squibb
At a glance
- Drug Originator PDL BioPharma
- Drug Licenced by Bristol-Myers Squibb
- Drug Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD319 antigen modulators; Natural killer cell stimulants
- USA Patent Applicants BRISTOL MYERS SQUIBB
- USA Patents 50
- BLAs 1
- International Patents 234

Disclaimer